Text Size

Downregulation of COL12A1 and COL13A1 by a selective EP2 receptor agonist, omidenepag, in human trabecular meshwork cells

Kumon M, Fuwa M, Shimazaki A, Odani-Kawabata N, Iwamura R, Yoneda K, Kato M.


  • 2023
  • PLoS One
View publication
  • Therapeutic Area

    Glaucoma

  • Categories

    Disease understanding (epidemiology, diagnosis, QoL, Biomarkers…)

  • Affiliations

    Product Development Division, Santen Pharmaceutical Co., Ltd., Nara, Japan; Product Development Division, Santen Pharmaceutical Co., Ltd., Osaka, Japan; Pharmaceutical Division, Pharmaceuticals Research Laboratory, UBE Corporation, Yamaguchi, Japan.

Related Publications

Associations between Clustered Visual Field Progression and Locations of Disc Hemorrhages in Glaucoma: A Three-year Prospective Study

Akagi T.; Fukuchi T.; Higashide T.; Udagawa S.; Ohkubo S.; Sugiyama K.; Tanihara H.; Araie M.; Tomita G.; Matsumoto C.; Tomidokoro A.; Hangai M.; Kawata H.; Inai M.; Tanaka Y.; SVF Prospector Study Group


Proteome-Wide Analysis of Autoantibodies in Open-Angle Glaucoma in Japanese Population: A Pilot Study

Takada N.; Ishikawa M.; Sato K.; Kunikata H.; Ninomiya T.; Hanyuda A.; Fukuda E.; Yamaguchi K.; Ono C.; Kirihara T.; Shintani C.; Tsusu C.; Osanai A.; Goshima N.; Izumi Y.; Zorumski C.F.; Nakazawa T.


Bioequivalence of Preservative-free and Preserved Omidenepag Isopropyl (OMDI) 0.002% Ophthalmic Solutions in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension: Results from the Phase 3 DAISY Study

Aihara M.; Lu F.; Ikeda T.; Odani-Kawabata N.


Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022